Combination immunotherapy + VEGF targeted therapy is the optimal systemic strategy for metastatic RCC

Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Department of Hematology/Oncology discusses Combination immunotherapy + VEGF targeted therapy is the optimal systemic strategy for metastatic RCC at the Kidney Cancer Meeting in Chiacgo